
    
      The safety run-in stage (Stage 1) will assess the safety of polatuzumab vedotin plus
      rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) in 10 participants. The randomized
      controlled trial (RCT) (Stage 2) will compare Pola-R-GemOx versus R-GemOx in 206
      participants.
    
  